Despoina Kyriakou

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12

“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group

Eirini Katodritou, Chrysanthi Vadikolia, Chrysavgi Lalagianni et al. · Annals of Hematology · 2013 · 39 citations

Medicine, Pharmacology, Pharmacotherapy +16

Deferoxamine treatment during early pregnancy: absence of teratogenicity in two cases.

E Vaskaridou, K Konstantopoulos, Despoina Kyriakou et al. · PubMed · 1993 · 30 citations

Medicine, Obstetrics, Pharmacology +15

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Eirini Katodritou, Marie‐Christine Kyrtsonis, Sosana Delimpasi et al. · Annals of Hematology · 2018 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Relationship between the paraoxonase 1 (PON1) M55L and Q192R polymorphisms and lymphohaematopoietic cancers in a Greek agricultural population

Maria Kokouva, Michalis Koureas, Efthimios Dardiotis et al. · Toxicology · 2012 · 15 citations

Medicine, Genetics, Molecular Genetics +13